
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 2.050 | 2.050 | 0.000 |
Shares | 97.950 | 97.950 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 26.246 | 18.647 |
Price to Book | 5.551 | 3.060 |
Price to Sales | 5.363 | 2.274 |
Price to Cash Flow | 19.309 | 12.145 |
Dividend Yield | 1.485 | 2.050 |
5 Years Earnings Growth | 8.474 | 9.680 |
Name | Net % | Category Average |
---|---|---|
Technology | 32.650 | 24.378 |
Financial Services | 23.810 | 16.889 |
Consumer Defensive | 12.970 | 7.317 |
Healthcare | 11.780 | 12.122 |
Industrials | 8.410 | 12.126 |
Consumer Cyclical | 6.710 | 10.393 |
Communication Services | 3.660 | 8.170 |
Number of long holdings: 39
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Microsoft | US5949181045 | 9.50 | 520.56 | -1.64% | |
SAP | DE0007164600 | 7.82 | 239.000 | +3.02% | |
Visa A | US92826C8394 | 6.35 | 342.55 | +1.73% | |
L'Oreal | FR0000120321 | 4.66 | 388.15 | +2.32% | |
Aon | IE00BLP1HW54 | 4.17 | 370.92 | +1.95% | |
Coca-Cola | US1912161007 | 3.68 | 70.46 | -0.35% | |
Booking | US09857L1089 | 3.61 | 5,453.57 | -0.15% | |
Alphabet A | US02079K3059 | 3.58 | 201.91 | -0.70% | |
Relx | GB00B2B0DG97 | 3.51 | 3,499.00 | -0.99% | |
Accenture | IE00B4BNMY34 | 3.45 | 245.69 | +3.29% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Adamant Medtech B USD | 1.35B | 4.77 | 8.42 | 9.36 | ||
Adamant Medtech I USD | 1.35B | 5.13 | 9.18 | 10.13 | ||
EDM Intl S American Growth A USD | 316.41M | 5.57 | 17.94 | 11.86 | ||
LU1811047247 | 185.48M | 4.94 | 7.13 | - | ||
LU1811047593 | 185.48M | 4.64 | 6.39 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review